VEKTIS
VEKTIS (NCT01751126) was a phase III, multicentre, randomised, double-masked, vehicle-controlled, parallel-arm trial that included a 4-month efficacy/safety evaluation period and an 8-month double-masked safety follow-up period [Both studies were conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Independent ethics committees and regulatory agencies (as appropriate) approved the study protocol before the trial was initiated (Supplementary Table 